ATE370147T1 - Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors - Google Patents

Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors

Info

Publication number
ATE370147T1
ATE370147T1 AT02713341T AT02713341T ATE370147T1 AT E370147 T1 ATE370147 T1 AT E370147T1 AT 02713341 T AT02713341 T AT 02713341T AT 02713341 T AT02713341 T AT 02713341T AT E370147 T1 ATE370147 T1 AT E370147T1
Authority
AT
Austria
Prior art keywords
thiazolopyrimidene
antagonists
derivatives
cx3cr1 receptor
cx3cr1
Prior art date
Application number
AT02713341T
Other languages
English (en)
Inventor
Sverker Hanson
Gunnar Nordvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE370147T1 publication Critical patent/ATE370147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02713341T 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors ATE370147T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use

Publications (1)

Publication Number Publication Date
ATE370147T1 true ATE370147T1 (de) 2007-09-15

Family

ID=20283552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713341T ATE370147T1 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors

Country Status (9)

Country Link
US (1) US7067657B2 (de)
EP (1) EP1377590B1 (de)
JP (1) JP2004524351A (de)
AT (1) ATE370147T1 (de)
AU (1) AU2002245005A1 (de)
DE (1) DE60221813T2 (de)
ES (1) ES2290277T3 (de)
SE (1) SE0101082D0 (de)
WO (1) WO2002076990A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313632D0 (en) * 2003-06-12 2003-07-16 Neuro Targets Ltd Chemokine receptors
EP1520586A1 (de) * 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibierung von Fractalkin oder von dessen Rezeptor zur Behandlung von atopishen Allergien
KR20060120014A (ko) * 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
US20100215663A1 (en) * 2006-02-15 2010-08-26 Northwestern University Methods and compositions for regulation of neurological conditions
AU2007300749B2 (en) 2006-09-29 2011-08-25 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3H)-amine derivatives and their use in therapy
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2913060A1 (de) 2014-02-28 2015-09-02 Universite De Nice Sophia-Antipolis Hemmung der Fraktalkin-Rezeptorinteraktion zur Behandlung von atopischer Dermatitis
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines

Also Published As

Publication number Publication date
AU2002245005A1 (en) 2002-10-08
WO2002076990A1 (en) 2002-10-03
WO2002076990A8 (en) 2002-11-14
EP1377590A1 (de) 2004-01-07
ES2290277T3 (es) 2008-02-16
DE60221813D1 (de) 2007-09-27
JP2004524351A (ja) 2004-08-12
US7067657B2 (en) 2006-06-27
EP1377590B1 (de) 2007-08-15
US20040106628A1 (en) 2004-06-03
DE60221813T2 (de) 2008-05-08
SE0101082D0 (sv) 2001-03-27

Similar Documents

Publication Publication Date Title
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
BR0311494A (pt) Novos indóis substituìdos
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20052733L (no) C-6 modifiserte indazolylpyrrolotriaziner
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
ATE411985T1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
MY138352A (en) Benzothiazole derivatives
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
ATE466860T1 (de) Cgrp-rezeptorantagonisten
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PT1337535E (pt) Derivados de benzodiazepina
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
DE60112574D1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
NO20072060L (no) 2-acylaminotiazolderivater
MXPA06000957A (es) Compuestos de n-sulfonil heterociclopirrolilalquilamina como ligandos de 5-hidroxitriptamina-6.
DE602006017849D1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties